---
document_datetime: 2025-12-29 11:28:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/apretude.html
document_name: apretude.html
version: success
processing_time: 0.1085114
conversion_datetime: 2025-12-30 08:01:26.410476
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Apretude

[RSS](/en/individual-human-medicine.xml/67707)

##### Authorised

This medicine is authorised for use in the European Union

cabotegravir Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Apretude](#news-on)
- [More information on Apretude](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Apretude is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. It should be used in combination with safer sex practices, such as using condoms.

Apretude contains the active substance cabotegravir.

Expand section

Collapse section

## How is Apretude used?

The medicine can only be obtained with a prescription and treatment should be prescribed by a healthcare professional who has experience in the management of HIV PrEP.

Apretude is available as tablets and as a prolonged-release injection. 'Prolonged release' means that the active substance is released slowly over a few weeks after being injected. The injection must be given by a healthcare professional. It is given once a month for the first 2 injections, and then every 2 months.

Alternatively, people may start with the tablets, which are taken once a day for 1 month. Use of the tablets is expected to allow quicker recovery in case of side effects. If the tablets are tolerated without side effects, the individual should be switched to the injection after 1 month.

For more information about using Apretude, see the package leaflet or contact your doctor or pharmacist.

## How does Apretude work?

Cabotegravir is an integrase inhibitor. It blocks an enzyme called integrase that the HIV-1 virus needs to make new copies of itself in the body. In case of exposure to the virus this will reduce the risk of the virus multiplying and spreading from the site of infection.

## What benefits of Apretude have been shown in studies?

Two main studies have evaluated Apretude for pre-exposure prophylaxis. In one study Apretude was compared with standard PrEP (tenofovir disoproxil fumarate/emtricitabine) in HIV-negative cisgender men and transgender women who have sex with men. Of 2,278 people who took Apretude, 12 tested positive for HIV-1 infection around 3 years (153 weeks) after treatment. This compared with 39 out of 2,281 people who took the standard treatment.

The second study involved over 3,200 HIV-negative cisgender women and compared Apretude with standard PrEP (tenofovir disoproxil fumarate/emtricitabine). Of the individuals taking Apretude, 3 out of 1,613 tested positive for HIV-1 infection 1 year after treatment compared with 36 out of 1,610 of those taking standard PrEP.

## What are the risks associated with Apretude?

For the full list of side effects and restrictions with Apretude, see the package leaflet.

The most common side effects with Apretude (which may affect more than 1 in 10 people) include injection site reactions, headache, diarrhoea and increase in the liver enzyme transaminase.

Apretude must not be used in people who have not been tested for HIV infection or who are positive for HIV infection. Apretude must also not be used together with some other medicines such as rifampicin, rifapentine, carbamazepine, oxcarbazepine, phenytoin or phenobarbital.

## Why is Apretude authorised in the EU?

The main studies showed that Apretude is effective at reducing the risk of HIV infection and overall it was well tolerated. Injection site reactions were generally mild and their risk decreased over duration of use. More serious side effects resulting in altered thinking or behaviour have been uncommonly reported in people with a pre-existing psychiatric disease and are managed with recommendations for counselling before and during treatment.

The European Medicines Agency therefore decided that Apretude's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Apretude?

The company that markets Apretude will provide a guide to doctors and individuals who use the medicine with information about the use of Apretude. Healthcare professionals will also receive a checklist to follow when prescribing and using the medicine and a reminder card to hand out to individuals receiving Apretude for PrEP.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Apretude have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Apretude are continuously monitored. Suspected side effects reported with Apretude are carefully evaluated and any necessary action taken to protect patients.

## Other information about Apretude

Apretude received a marketing authorisation valid throughout the EU on 15 September 2023.

Apretude : EPAR - Medicine overview

Reference Number: EMA/341424/2023

English (EN) (120.58 KB - PDF)

**First published:** 20/09/2023

[View](/en/documents/overview/apretude-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-897)

български (BG) (145.36 KB - PDF)

**First published:**

20/09/2023

[View](/bg/documents/overview/apretude-epar-medicine-overview_bg.pdf)

español (ES) (120.97 KB - PDF)

**First published:**

20/09/2023

[View](/es/documents/overview/apretude-epar-medicine-overview_es.pdf)

čeština (CS) (143.58 KB - PDF)

**First published:**

20/09/2023

[View](/cs/documents/overview/apretude-epar-medicine-overview_cs.pdf)

dansk (DA) (118.56 KB - PDF)

**First published:**

20/09/2023

[View](/da/documents/overview/apretude-epar-medicine-overview_da.pdf)

Deutsch (DE) (123.32 KB - PDF)

**First published:**

20/09/2023

[View](/de/documents/overview/apretude-epar-medicine-overview_de.pdf)

eesti keel (ET) (118.58 KB - PDF)

**First published:**

20/09/2023

[View](/et/documents/overview/apretude-epar-medicine-overview_et.pdf)

ελληνικά (EL) (145.58 KB - PDF)

**First published:**

20/09/2023

[View](/el/documents/overview/apretude-epar-medicine-overview_el.pdf)

français (FR) (121.49 KB - PDF)

**First published:**

20/09/2023

[View](/fr/documents/overview/apretude-epar-medicine-overview_fr.pdf)

hrvatski (HR) (140.73 KB - PDF)

**First published:**

20/09/2023

[View](/hr/documents/overview/apretude-epar-medicine-overview_hr.pdf)

italiano (IT) (119.23 KB - PDF)

**First published:**

20/09/2023

[View](/it/documents/overview/apretude-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (160.01 KB - PDF)

**First published:**

20/09/2023

[View](/lv/documents/overview/apretude-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.94 KB - PDF)

**First published:**

20/09/2023

[View](/lt/documents/overview/apretude-epar-medicine-overview_lt.pdf)

magyar (HU) (142.98 KB - PDF)

**First published:**

20/09/2023

[View](/hu/documents/overview/apretude-epar-medicine-overview_hu.pdf)

Malti (MT) (145.58 KB - PDF)

**First published:**

20/09/2023

[View](/mt/documents/overview/apretude-epar-medicine-overview_mt.pdf)

Nederlands (NL) (120.16 KB - PDF)

**First published:**

20/09/2023

[View](/nl/documents/overview/apretude-epar-medicine-overview_nl.pdf)

polski (PL) (146.48 KB - PDF)

**First published:**

20/09/2023

[View](/pl/documents/overview/apretude-epar-medicine-overview_pl.pdf)

português (PT) (121.87 KB - PDF)

**First published:**

20/09/2023

[View](/pt/documents/overview/apretude-epar-medicine-overview_pt.pdf)

română (RO) (140.66 KB - PDF)

**First published:**

20/09/2023

[View](/ro/documents/overview/apretude-epar-medicine-overview_ro.pdf)

slovenčina (SK) (143.66 KB - PDF)

**First published:**

20/09/2023

[View](/sk/documents/overview/apretude-epar-medicine-overview_sk.pdf)

slovenščina (SL) (168.91 KB - PDF)

**First published:**

20/09/2023

[View](/sl/documents/overview/apretude-epar-medicine-overview_sl.pdf)

Suomi (FI) (118.7 KB - PDF)

**First published:**

20/09/2023

[View](/fi/documents/overview/apretude-epar-medicine-overview_fi.pdf)

svenska (SV) (119.4 KB - PDF)

**First published:**

20/09/2023

[View](/sv/documents/overview/apretude-epar-medicine-overview_sv.pdf)

Apretude : EPAR - Risk management plan

English (EN) (1.24 MB - PDF)

**First published:** 20/09/2023

**Last updated:** 19/02/2025

[View](/en/documents/rmp/apretude-epar-risk-management-plan_en.pdf)

## Product information

Apretude : EPAR - Product information

English (EN) (1.09 MB - PDF)

**First published:** 20/09/2023

**Last updated:** 19/02/2025

[View](/en/documents/product-information/apretude-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-908)

български (BG) (1.72 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/bg/documents/product-information/apretude-epar-product-information_bg.pdf)

español (ES) (1.21 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/es/documents/product-information/apretude-epar-product-information_es.pdf)

čeština (CS) (1.24 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/cs/documents/product-information/apretude-epar-product-information_cs.pdf)

dansk (DA) (1.23 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/da/documents/product-information/apretude-epar-product-information_da.pdf)

Deutsch (DE) (1.24 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/de/documents/product-information/apretude-epar-product-information_de.pdf)

eesti keel (ET) (1.13 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/et/documents/product-information/apretude-epar-product-information_et.pdf)

ελληνικά (EL) (1.23 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/el/documents/product-information/apretude-epar-product-information_el.pdf)

français (FR) (1.23 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/fr/documents/product-information/apretude-epar-product-information_fr.pdf)

hrvatski (HR) (1.15 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/hr/documents/product-information/apretude-epar-product-information_hr.pdf)

íslenska (IS) (1.21 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/is/documents/product-information/apretude-epar-product-information_is.pdf)

italiano (IT) (1.16 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/it/documents/product-information/apretude-epar-product-information_it.pdf)

latviešu valoda (LV) (1.17 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/lv/documents/product-information/apretude-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.24 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/lt/documents/product-information/apretude-epar-product-information_lt.pdf)

magyar (HU) (1.25 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/hu/documents/product-information/apretude-epar-product-information_hu.pdf)

Malti (MT) (1.2 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/mt/documents/product-information/apretude-epar-product-information_mt.pdf)

Nederlands (NL) (1.23 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/nl/documents/product-information/apretude-epar-product-information_nl.pdf)

norsk (NO) (1.22 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/no/documents/product-information/apretude-epar-product-information_no.pdf)

polski (PL) (1.27 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/pl/documents/product-information/apretude-epar-product-information_pl.pdf)

português (PT) (1.13 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/pt/documents/product-information/apretude-epar-product-information_pt.pdf)

română (RO) (1.21 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/ro/documents/product-information/apretude-epar-product-information_ro.pdf)

slovenčina (SK) (1.21 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/sk/documents/product-information/apretude-epar-product-information_sk.pdf)

slovenščina (SL) (1.2 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/sl/documents/product-information/apretude-epar-product-information_sl.pdf)

Suomi (FI) (1.24 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/fi/documents/product-information/apretude-epar-product-information_fi.pdf)

svenska (SV) (1.17 MB - PDF)

**First published:**

20/09/2023

**Last updated:**

19/02/2025

[View](/sv/documents/product-information/apretude-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00000116/202403 09/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Apretude : EPAR - All authorised presentations

English (EN) (66.84 KB - PDF)

**First published:** 20/09/2023

[View](/en/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-669)

български (BG) (58.97 KB - PDF)

**First published:**

20/09/2023

[View](/bg/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.41 KB - PDF)

**First published:**

20/09/2023

[View](/es/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_es.pdf)

čeština (CS) (50.91 KB - PDF)

**First published:**

20/09/2023

[View](/cs/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.46 KB - PDF)

**First published:**

20/09/2023

[View](/da/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (42.08 KB - PDF)

**First published:**

20/09/2023

[View](/de/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (66.7 KB - PDF)

**First published:**

20/09/2023

[View](/et/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (57.69 KB - PDF)

**First published:**

20/09/2023

[View](/el/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_el.pdf)

français (FR) (41.47 KB - PDF)

**First published:**

20/09/2023

[View](/fr/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (84.51 KB - PDF)

**First published:**

20/09/2023

[View](/hr/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (41.81 KB - PDF)

**First published:**

20/09/2023

[View](/is/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_is.pdf)

italiano (IT) (66.37 KB - PDF)

**First published:**

20/09/2023

[View](/it/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (60.56 KB - PDF)

**First published:**

20/09/2023

[View](/lv/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (84.98 KB - PDF)

**First published:**

20/09/2023

[View](/lt/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (74.53 KB - PDF)

**First published:**

20/09/2023

[View](/hu/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (88.18 KB - PDF)

**First published:**

20/09/2023

[View](/mt/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.47 KB - PDF)

**First published:**

20/09/2023

[View](/nl/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (42.25 KB - PDF)

**First published:**

20/09/2023

[View](/no/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_no.pdf)

polski (PL) (87.4 KB - PDF)

**First published:**

20/09/2023

[View](/pl/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_pl.pdf)

português (PT) (68.24 KB - PDF)

**First published:**

20/09/2023

[View](/pt/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_pt.pdf)

română (RO) (60.74 KB - PDF)

**First published:**

20/09/2023

[View](/ro/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (64.05 KB - PDF)

**First published:**

20/09/2023

[View](/sk/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (62.52 KB - PDF)

**First published:**

20/09/2023

[View](/sl/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (44.62 KB - PDF)

**First published:**

20/09/2023

[View](/fi/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.44 KB - PDF)

**First published:**

20/09/2023

[View](/sv/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Apretude Active substance cabotegravir International non-proprietary name (INN) or common name cabotegravir Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AJ04

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4.2, 4.4 and 5.1).

## Authorisation details

EMA product number EMEA/H/C/005756 Marketing authorisation holder

ViiV Healthcare B.V.

Van Asch van Wijckstraat 55 H

Opinion adopted 20/07/2023 Marketing authorisation issued 15/09/2023 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Apretude : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (162.31 KB - PDF)

**First published:** 19/02/2025

[View](/en/documents/procedural-steps-after/apretude-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Apretude-H-C-PSUSA-00000116-202403 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/43280/2025

English (EN) (135.17 KB - PDF)

**First published:** 19/02/2025

[View](/en/documents/scientific-conclusion/apretude-h-c-psusa-00000116-202403-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Apretude-H-C-005756-II-0004 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/18540/2025

English (EN) (2.8 MB - PDF)

**First published:** 19/02/2025

[View](/en/documents/variation-report/apretude-h-c-005756-ii-0004-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Apretude : EPAR - Public assessment report

Adopted

Reference Number: EMA/360205/2023

English (EN) (6.39 MB - PDF)

**First published:** 20/09/2023

[View](/en/documents/assessment-report/apretude-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Apretude

Adopted

Reference Number: EMA/327881/2023

English (EN) (139.76 KB - PDF)

**First published:** 21/07/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-apretude_en.pdf)

#### News on Apretude

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023) 21/07/2023

#### More information on Apretude

- [An observational study evaluating long-acting injectable cabotegravir (CAB-LA; APRETUDE) healthcare provider and user experience and utilization for pre-exposure prophylaxis (PrEP) against HIV in Canada (223857) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000801)
- [Prospective Study to Assess Usage, Adherence, Effectiveness of Cabotegravir LA for Pre-Exposure Prophylaxis in the United States in the OPERA Cohort (219844) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000165)
- [Frequency of HIV diagnoses among people using oral and LA PrEP - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000371)
- [CAB LA PrEP Cohort: Prospective Cohort Study to Assess Effectiveness and Safety of, and Adherence and Resistance to Cabotegravir for Pre-Exposure Prophylaxis in the United States (217671) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000163)
- [CAB LA PrEP Cohort: Prospective Cohort Study to Assess Adherence and Effectiveness of, and Monitor for Hepatotoxicity and Resistance to, Cabotegravir for Pre-Exposure Prophylaxis in Europe (221935) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000299)

**This page was last updated on** 19/02/2025

## Share this page

[Back to top](#main-content)